CPX treatment improves long-term reconstitution capability of cultured CB-CD34⁺ cells. (A) Schematic representation of transplantation experiment. (B) Percentage of human CD45⁺ cells in the PB (6, 12, 16 weeks) and (C) BM (16 weeks) of NSG recipients. (D-E) Representative FACS plots and quantification of lineage distribution for B cells (CD19) and myeloid cells (CD33/CD15) in BM. (F-G) Secondary transplantation: human chimerism level in PB (F) and BM (G) of secondary NSG recipients from 16 to 18 weeks after transplantations.